To indentify factors underlying improved insulin sensitivity and glucose utilization, we evaluated levels of transcripts encoding inflammatory mediators in eWAT, iWAT, MG and MS from db/db mice treated and untreated with TA-1887.17, 18 Expression of several inflammatory mediators such as IL-6, IL-1b, MCP1, CD68 and mmp12 decreased, particularly in eWAT and iWAT, in TA-1887-treated mice relative to untreated controls, and some reduction in inflammatory markers was seen in MG and MS (Fig. 3a). This evidence concerns the gene IL1B and myeloid sarcoma.